Quantitative dual-energy CT for evaluating hepatocellular carcinoma after transarterial chemoembolization

Xiaofei Yue1,2,4, Qiqi Jiang1,2,4, Xuehan Hu2,3, Chunyuan Cen1,2, Songlin Song1,2, Kun Qian1,2, Yuting Lu1,2, Ming Yang1,2, Qian Li1,2 & Ping Han1,2*

We aimed to investigate the role of the quantitative parameters of dual-energy computed tomography (DECT) in evaluating patients with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE). We retrospectively identified 80 HCC patients (mean age, 56 years; 61 men) treated by TACE who received contrast-enhanced DECT and were retreated by TACE within 7 days between November 2018 and December 2019. Taking digital subtraction angiography (DSA) and CT images as reference standard, two readers measured and calculated the values of normalized iodine concentration at arterial phase (NICAP), normalized iodine concentration at portal venous phase (NICPP), iodine concentration difference (ICD), arterial iodine fraction (AIF) and slope of the spectral Hounsfield unit curve ($\lambda_{Hu}$) by placing matched regions of interests (ROIs) within the tumor active area (TAA), adjacent normal hepatic parenchyma (ANHP) and tumor necrotic area (TNA). Differences between the parameters were analyzed by the Kruskal–Wallis H test. Receiver operating characteristic analysis of the parameters performance in differentiating the three tissues types was performed. AIF exhibited a good performance in distinguishing TAA (0.93 ± 0.31) and ANHP (0.18 ± 0.14), the areas under the receiver operating characteristic curve (AUC) was 0.989, while the $\lambda_{Hu}$ exhibited an excellent performance in distinguishing TAA (3.32 ± 1.24) and TNA (0.29 ± 0.27), with an AUC of 1.000. In conclusion, quantitative DECT can be effectively used to evaluate the tumor viability in HCC patients treated by TACE.

Abbreviations

HCC  Hepatocellular carcinoma
TACE  Transarterial chemoembolization
NICAP  Normalized iodine concentration at arterial phase
NICPP  Normalized iodine concentration at portal venous phase
$\lambda_{Hu}$  Slope of spectral Hounsfield unit curve
ICD  Iodine concentration difference
AIF  Arterial iodine fraction
TAA  Tumor active area
ANHP  Adjacent normal hepatic parenchyma
TNA  Tumor necrotic area

Hepatocellular carcinoma (HCC) is a common malignant tumor. The incipient symptoms of HCC are usually atypical1. Many patients are at Barcelona clinic liver cancer (BCLC) stage C at diagnosis2 and have lost the opportunity for curative surgery, resulting in a poor prognosis3. At present, the nonsurgical treatments of HCC consist mainly of radiofrequency ablation, microwave thermal ablation, transarterial chemoembolization (TACE), radiotherapy and systemic chemotherapy4.

1Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. 2Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China. 3Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. 4These authors contributed equally: Xiaofei Yue and Qiqi Jiang. *email: hanping_uh@hust.edu.cn
TACE is the first-line treatment for the intermediate stage of HCC according to the BCLC system. Using angiography, embolic agents and chemotherapeutic drugs are injected into the supply artery of the tumor, thereby reducing the blood supply and curbing disease progression. However, TACE is complicated by postoperative recurrence. Hence, imaging evaluation after TACE is very important. The revised Response Evaluation Criteria in Solid Tumors (mRECIST) proposed in 2010 and the Liver Imaging Reporting and Data System (LI-RADS) version 2018 both set standards for the treatment response of liver cancer. The treatment response standards of both protocols are based on imaging features rather than a quantitative evaluation.

Conventional enhanced CT is an inexpensive, and convenient scan commonly used for post-TACE review of HCC. Nonetheless, the mixed energy image of a conventional CT scan may give rise to ray beam-hardening artifacts, and the high density of lipiodol deposition may cause a shielding effect on adjacent structures that affects the visual observation and evaluation.

Dual-energy computed tomography (DECT) provides a wide selection of dual energies by using stronger penetrating 150 Sn kV X-rays. The efficiency of X-rays is improved by the "spectral filtering" effect, which contributes to a precise substance separation. Iodine quantification is more accurate than standard enhancement measurements and DECT offers the measurement of iodine uptake rather than mere enhancement values. Parameters of DECT such as slope of spectral Hounsfield unit curve (λHu) and arterial iodine fraction (AIF) are quantitative parameters that cannot be obtained with conventional CT. Such measurements could effectively compensate for the lack of quantification on conventional CT.

The purpose of this study was to quantitatively differentiate the tumor active area (TAA), adjacent normal hepatic parenchyma (ANHP) and tumor necrotic area (TNA) after TACE using DECT parameters, thus providing an alternative method for the follow-up of patients with HCC and that may be used as a supplement to LI-RADS v2018.

Methods
The protocol for this single-center study was approved by the Ethics Committee of Tongji Medical College of Huazhong University of Science and Technology and performed in accordance with the guidelines of the Declaration of Helsinki. All methods were performed in accordance with the relevant guidelines and regulations. All patients signed informed consent forms.

Patient demographics. Between November 2018 and December 2019, 80 consecutive patients (61 men, 19 women) with HCC who underwent conventional TACE (C-TACE) (68 patients) or drug-eluting microsphere transarterial chemoembolization (DEM-TACE) (12 patients) intervention in the preceding 1–3 months were included in this study. Patients were enrolled according to the following criteria: (a) diagnosed with HCC; (b) underwent TACE intervention in the preceding 1–3 months; (c) were to be retreated with TACE within 7 days after CT review. Among the 159 patients who were initially deemed qualified for the study, 79 were excluded for the following reasons: (a) could not achieve the required injection rate (3.5 mL/s) (n = 5); (b) was not retreated with TACE within 7 days or did not undergo retreatment with TACE within 7 days or were considered to have absolute contraindication for TACE (n = 25); (c) no TAA in CT images and DSA images (n = 10); (d) extensive lipiodol deposition, the area of non-lipiodol deposition regions was less than 0.5 cm², leading to inaccurate measurement (n = 30); and (e) diffuse HCC with no ANHP to measure (n = 9). Figure 1 presents the patient enrollment workflow diagram.

CT examinations. First, 1.2 mL/kg of iodine contrast medium (iodixanol, 320 mg I/mL; Hengrui Healthcare, Jiangsu, China) was intravenously injected. Then, third-generation dual-source CT (SOMATOM Force, Siemens Healthcare, Forchheim, Germany) was performed with multiple phases. Patients were instructed to fast for four hours before the CT scan.

All patients were positioned with their arms up on the scanning table in the supine position. Scanning was performed from the top of the diaphragm to the lower edge of the liver. First, an unenhanced CT scan of the abdomen was performed with a dual-energy model. Enhanced CT acquisitions were triggered using the bolus
to avoid measurement errors, and the results were averaged. On whichever had the smaller ROI. All data were measured at different times by two independent radiologists calculated. All of the ROIs of one person were of the same size and at the same level of the scan, which depended analyses were performed with statistical software (SPSS, version 21.0, IBM Corporation, Armonk, NY, USA; CT value was gauged on 40 keV images, and HU70keV indicates that the CT value was gauged on 70 keV images. Statistical analyses. Chemotherapeutic drugs and embolic agents were mixed together and injected through the blood supply artery angiography was performed, and attention was paid to finding collateral blood supply. The location, size, number and blood supply arteries of the tumor were determined by careful analysis of the angiographic findings. The chemotherapeutic drugs and embolic agents were mixed together and injected through the blood supply artery branch of the tumor.

Reference standard. Taking the DSA and CT images as references standard, two abdominal radiologists with more than five years of experience independently interpreted the CT images according to LI-RADS standards but were blinded to the DSA results. LI-RADS-Treatment Response (LR-TR) Viable was considered to be TAA with nodular, mass-like, or thick irregular tissue in or along the treated lesion with any of the following: arterial phase hyperenhancement; washout appearance; or enhancement similar to pretreatment. Two interventionists with more than ten years of experience interpreted the TACE on picture archiving and communication system (PACS) and were blinded to the CT results; TAA was considered to exist when tumor staining was observed. A senior radiologist was consulted for any disagreement. Vital tissue was considered to exist when both the TACE and CT results suggested TAA.

TACE retreatment. Digital subtraction angiography (DSA) examination is a part of TACE retreatment, and we only collected data from patients who required retreatment clinically without additional examinations. The Seldinger method is used to intubate the femoral artery via percutaneous puncture and insert the catheter into the abdominal trunk or common hepatic artery for DSA to acquire DSA images. Superior mesenteric artery was conducted 24-s after the end of the arterial phase. The scanning protocol was as follows: collimator width, 128 × 0.6 mm; field of view (FOV), 300 mm; and pitch, 0.6. Tube A was operated at a peak voltage of 100 kV and 180 quality reference mAs (Siemens Healthcare). Tube B was operated at 150 Sn kV and 90 quality reference mAs. The data were reconstructed with a slice thickness of 1.5 mm.

Postprocessing of DECT images. Images were transferred to a postprocessing software workstation (Syngo via, Siemens Healthcare). When there were multiple lesions, the three largest lesions were selected for measurement. Two types of reconstructed images were measured: color-coded iodine maps and monoenergetic images of 151 energies ranging from 40 to 190 keV. All ROIs of TAA, ANHP, TNA and abdominal aorta were manually plotted at the same location and size on arterial phase and portal venous phase to obtain the values of iodine concentration (IC) and standardized iodine concentration (NIC) on the iodine map. Spectral Hounsfield unit curves were obtained from the monoenergetic images of arterial phase. The normalized iodine concentration at arterial phase (NICAP), normalized iodine concentration at portal venous phase (NICPP), iodine concentration difference (ICD), arterial iodine fraction (AIF) and the slope of the spectral Hounsfield unit curve (λHu) were then calculated (Table 1).

The λHu was calculated as: λHu = (HU40keV − HU70keV)/30 on arterial phase. The HU40keV indicates that the CT value was gauged on 40 keV images, and HU70keV indicates that the CT value was gauged on 70 keV images. The NIC was calculated as: NIC = IClesion/ICaorta, where IClesion and ICaorta are the iodine level of the lesion and the aorta on the same slice, respectively; the iodine concentration in the lesion is normalized to the aortic iodine concentration to minimize the difference between patients. The ROIs of TAA, NAHP and TNA were round and were selected to avoid large blood vessels, iodized oil deposits and surrounding artifacts. For TNA, the area was selected in TACE-treated tumors that were not enhanced after repeated measurements by radiologists in three-phase enhanced images and single-energy images. ANHP was chosen to be close to the tumor and 1 cm away from it to avoid possible effects of microvascular invasion on the measured iodine concentration. When measuring nodular lesions, tumor tissues were included as much as possible. When measuring massive lesions, multiple points were measured, and the mean values were calculated. All of the ROIs of one person were of the same size and at the same level of the scan, which depended on whichever had the smaller ROI. All data were measured at different times by two independent radiologists to avoid measurement errors, and the results were averaged.

Table 1. Calculation formula of each parameter.

| Parameters                  | Full name                                      | Formula                                      |
|-----------------------------|------------------------------------------------|----------------------------------------------|
| NICAP                       | Normalized iodine concentration at arterial phase | IClesion/ICAorta at arterial phase           |
| NICPP                       | Normalized iodine concentration at portal venous phase | IClesion/ICAorta at portal venous phase     |
| ICD                         | Iodine concentration difference                | IC arterial phase − IC venous phase          |
| AIF                         | Arterial iodine fraction                       | IC arterial phase/IC venous phase            |
| λHu                         | The slope of the spectral Hounsfield unit curve | (HU40keV − HU70keV)/30 at arterial phase     |

Statistical analyses. Continuous variables are reported as the mean ± standard deviation. All statistical analyses were performed with statistical software (SPSS, version 21.0, IBM Corporation, Armonk, NY, USA;
MedCalc, version 15.2.2, MedCalc, Mariakerke, Belgium). The Kolmogorov–Smirnov test was used to test for normality. Consistency between the two radiologists was assessed by using ICC. The Kruskal–Wallis H test was used to compare the differences between various TAA, ANHP and TNA parameters. A value of $P < 0.05$ was considered significant. The diagnostic performance of each parameter (TAA, ANHP and TNA) was compared by plotting the ROC curve.

**Results**

Relevant demographic and regions of interest (ROIs) characteristics were outlined in Table 2. The mean age at interview was 56 years, ranging from 24 to 78 years. A total of 80 patients (61 men and 19 women) were included in this study. A total of 445 ROIs were measured (194 in the TAA, 194 in the ANHP and 57 in the TNA). The ROIs ranged from 0.5 to 6.3 cm$^2$, with an average of 1.42 ± 0.92 cm$^2$. A total of 23 patients had single lesions, while 57 patients had multiple lesions.

**Intraclass correlation coefficients between two radiologists.** The intraclass correlation coefficients (ICC) of the TAA, ANHP and TNA measurements were evaluated. The agreements of the measured values were good (between 0.760 and 0.977). The results are shown in Table 3.

### Table 2. Patients and lesions characteristics on DECT. The data are represented as the mean ± standard deviation or number of patients. HCC, hepatocellular carcinoma; ROIs, regions of interests; TAA, tumor active area; ANHP, adjacent normal hepatic parenchyma; TNA, tumor necrotic area.

| Characteristics          | N  |
|--------------------------|----|
| Sex                      |    |
| Men                      | 61 |
| Women                    | 19 |
| Age (y)                  | 56 ±11 |
| Etiology of HCC          |    |
| Hepatitis B virus        | 60 |
| Alcoholism               | 1  |
| Hepatitis C virus        | 6  |
| Bilharziasis             | 3  |
| Cryptogenic              | 14 |
| No. of HCC lesions per patient |    |
| Single                   | 23 |
| Multiple                 | 57 |
| No. of ROIs              |    |
| ROIs of the TAA          | 194|
| ROIs of the ANHP         | 194|
| ROIs of the TNA          | 57 |

### Table 3. ICC of the measurements between two radiologists. ICAP, iodine concentration at arterial phase; ICPP, iodine concentration at portal venous phase; NICAP, normalized iodine concentration at arterial phase; NICPP, normalized iodine concentration at portal venous phase; TAA, tumor active area; ANHP, adjacent normal hepatic parenchyma; TNA, tumor necrotic area.

| Groups | Parameters | ICC   | 95%CI   |
|--------|------------|-------|---------|
| TAA    | ICAP       | 0.968 | 0.958–0.976 |
|        | NICAP      | 0.977 | 0.969–0.982 |
|        | ICPP       | 0.977 | 0.969–0.982 |
|        | NICPP      | 0.975 | 0.967–0.981 |
| ANHP   | ICAP       | 0.874 | 0.830–0.908 |
|        | NICAP      | 0.863 | 0.815–0.899 |
|        | ICPP       | 0.954 | 0.936–0.967 |
|        | NICPP      | 0.936 | 0.913–0.954 |
| TNA    | ICAP       | 0.813 | 0.703–0.885 |
|        | NICAP      | 0.760 | 0.627–0.850 |
|        | ICPP       | 0.933 | 0.890–0.959 |
|        | NICPP      | 0.940 | 0.900–0.964 |
Differences in dual-energy CT parameters between different tissues. The differences in parameters between different tissues are shown in Table 4. The $\lambda_{\text{Hu}}$, normalized iodine concentration at arterial phase (NICAP) and normalized iodine concentration at portal venous phase (NICPP) of the TAA were 3.32 ± 1.24, 16.51 ± 6.75% and 46.68 ± 15.10%, respectively, which were significantly higher than those in the ANHP (0.71 ± 0.39, 2.66 ± 2.05% and 39.48 ± 10.65%, respectively, P < 0.05) and TNA (0.29 ± 0.27, 1.49 ± 0.54% and 9.30 ± 7.46%, respectively, P < 0.05). The iodine concentration difference (ICD) of the TAA was 0.56 ± 0.46 mg/mL, which was lower than that of ANHP (1.49 ± 0.54 mg/mL). The AIF of the TAA was 0.93 ± 0.31, which was significantly higher than that of the ANHP (0.18 ± 0.14, P < 0.05) but not significantly different from the TNA (0.99 ± 0.86, P = 0.251). Figures 2, 3 and 4 provide representative images of the DECT parametric maps.

**Table 4.** Comparison of various parameters in different liver tissues after TACE. $\lambda_{\text{Hu}}$, slope of the spectral Hounsfield unit curve; NICAP, normalized iodine concentration at arterial phase; NICPP, normalized iodine concentration at portal venous phase; ICD, iodine concentration difference; AIF, arterial iodine fraction; TAA, tumor active area; ANHP, adjacent normal hepatic parenchyma; TNA, tumor necrotic area. *Indicates a significant difference between TAA and ANHP (P < 0.05). †Indicates a significant difference between TNA and ANHP (P < 0.05). & Indicates a significant difference between TAA and TNA (P < 0.05).

| Parameters | TAA (mean ± SD) | ANHP (mean ± SD) | TNA (mean ± SD) | P  |
|------------|----------------|------------------|----------------|----|
| $\lambda_{\text{Hu}}$ | 3.32 ± 1.24*   | 0.71 ± 0.39†     | 0.29 ± 0.27    | < 0.05 |
| NICAP (%)  | 16.51 ± 6.75*  | 2.66 ± 2.05      | 2.28 ± 1.47    | < 0.05 |
| NICPP (%)  | 46.68 ± 15.10* | 39.48 ± 10.65†   | 9.30 ± 7.46    | < 0.05 |
| ICD(mg/mL) | 0.56 ± 0.46*   | 1.49 ± 0.54†     | 0.29 ± 0.36    | < 0.05 |
| AIF        | 0.93 ± 0.31*   | 0.18 ± 0.14†     | 0.99 ± 0.86    | < 0.05 |

**Figure 2.** This is a patient who had a DECT examination 7 weeks after the conventional-TACE, showed that lipiodol deposited around the tumor, and TAA and TNA in the tumor after treatment. A large lesion with scattered lipiodol deposition is seen within the right lobe of the liver. The center non-enhancing area was TNA. Peripheral soft tissue nodularity is noted on axial non-enhanced CT (red arrow, A), with slight enhancement on arterial phase (B), and portal venous phase (C), which was considered by radiologists to be TAA. ROIs of TAA, ANHP, and TNA placed on arterial phase and portal phase iodine map (D and E) showed the IC and NIC of TAA to be 1.1 mg/ml and 8.5% at arterial phase, and 0.6 mg/ml and 15.3% at portal venous phase, respectively. The IC and NIC of ANHP was 0.3 mg/ml and 1.9% at arterial phase, and 1.8 mg/ml and 43.4% at portal venous phase, respectively. The IC and NIC of TNA was 0.4 mg/ml and 3.2% at arterial phase, and 0.8 mg/ml and 18.3% at portal venous phase, respectively. The $\lambda_{\text{Hu}}$ of TAA, ANHP and TNA were 1.57, 0.37 and 0.10, respectively (F).
There were no significant differences in the parameters results of 12 patients treated by DEM-TACE and 68 patients treated by lipiodol TACE. The corresponding results were added in the supplementary materials.

Diagnostic performance of the parameters across different tissues. The diagnostic performance of the parameters across different tissues is summarized in Table 5. The receiver operating characteristic (ROC) curve showed that λHu, NICAP, ICD, and AIF have a high efficiency for the differential diagnosis of the TAA and ANHP (areas under the ROC curve (AUC): 0.987, 0.988, 0.909, and 0.989, respectively). All of the parameters exhibited considerable sensitivity and specificity. The NICPP exhibited low efficiency for the discrimination of the TAA and ANHP (AUC 0.686). λHu, NICAP, and NICPP exhibited high performance for the differential diagnosis of the TAA and TNA (AUC: 1.000, 0.997, and 0.962, respectively). The ICD and AIF exhibited weak performance for the differential diagnosis of the TAA and TNA (AUC: 0.717, and 0.688, respectively) (Fig. 5).

Discussion
DECT has advantages in providing artifact reduction22, additional information regarding tissue composition23,24, and radiation dose reduction25. In this study, we found that the DECT parameters, especially λHu at the arterial phase and NICAP, showed high efficiency for discriminating the different tissues in patients with HCC, with an AUC values of 0.987 and 0.988, for the recognition of the TAA and ANHP, respectively, and an AUC values of 1.000, and 0.997 for the recognition of the TAA and TNA, respectively. The quantitative parameters of DECT may help physicians to judge the effect of treatment and make correct clinical decisions.

The linear decay coefficient of tissues decreases with increasing keV values. However, the decline rate of each tissue is different13,26, that is, the λHu can show energy attenuation and depends on the physical and chemical properties of the material itself. The CT value of the material is greatly attenuated when energy changes are maintained at a low level. The energy spectrum curve of the TAA measured in this study was steep and straight from 40keV to 70keV, consistent with the literature18,19. The λHu can significantly reflect the blood supply characteristics of different tissues at arterial phase. The λHu of different tissues in this study showed a decline with varying slopes, among which the λHu of the TAA was significantly larger than those of the ANHP and TNA. ROC analysis showed that the λHu was highly effective in discriminating various tissues. A value higher than 1.32 was more likely to indicate a TAA. Therefore, the λHu is of great value in the follow-up post TACE. Changes in the λHu in

Figure 3. DECT images of a 58-year-old man with HCC undergoing DEM-TACE 6 weeks ago, showed that no lipiodol deposition in the original tumor lesions, but TAA and TNA were present. The right hepatic lobe showed a low-attenuation lesion on unenhanced CT image (A), significant enhancement at arterial phase (B), and persistent enhancement at the portal venous phase (C). TNA had no enhancement. ROIs of TAA, ANHP, and TNA placed on arterial and portal iodine map (D and E) showed IC and NIC of TAA to be 1.5 mg/ml and 20.1% at arterial phase and 1.8 mg/ml and 48.5% at portal venous phase, respectively. The IC and NIC of ANHP was 0.3 mg/ml and 4.1% at arterial phase, and 1.1 mg/ml and 30.2% at portal venous phase, respectively. The IC and NIC of TNA was 0.1 mg/ml and 0.9% at arterial phase and 0.5 mg/ml and 11.9% at portal venous phase, respectively. The λHu of TAA, ANHP and TNA were 2.86, 0.53 and 0.23, respectively (F).
Colon cancer patients with varying degrees of differentiation have also been compared. The results showed that poorly differentiated or undifferentiated carcinoma had a larger \( \lambda_{Hu} \) than well-differentiated carcinoma, providing a feasible basis for the evaluation of the tumor pathology. Therefore, evaluation of the degree of differentiation of tumors after TACE should be further studied.

Functional information regarding the microcirculation of the normal parenchyma and liver focal tumor lesions can be provided by CT perfusion imaging of the liver, which is a promising technology for the diagnosis of hepatocellular carcinoma (HCC). Figure 4 shows DECT images of a 52-year-old man with HCC undergoing lipiodol TACE. The right hepatic lobe showed the original lesions were completely deposited with lipiodol, and the new lesions appeared as low-attenuation nodules on axial unenhanced CT image (A), significant enhancement at the arterial phase (B), and wash-out at the portal venous phase (C). ROIs of TAA and ANHP (D and E) placed on arterial and portal iodine map showed IC and NIC of TAA to be 2.3 mg/ml and 19.2% at arterial phase, and 2.1 mg/ml and 42.5% at portal venous phase. IC and NIC of ANHP was 0.1 mg/ml and 1.0% at arterial phase, and 2.1 mg/ml and 42.9% at portal venous phase. The \( \lambda_{Hu} \) of TAA and ANHP was 3.24 and 0.86, respectively (F).

Table 5. Diagnostic performance of each parameter in distinction of different tissues. \( \lambda_{Hu} \), Slope of the spectral Hounsfield unit curve; NICAP, normalized iodine concentration at arterial phase; NICPP, normalized iodine concentration at portal venous phase; ICD, iodine concentration difference; AIF, arterial iodine fraction; TAA, tumor active area; ANHP, adjacent normal hepatic parenchyma; TNA, tumor necrotic areas.

| Parameter | TAA and ANHP | | TAA and TNA | |
|-----------|--------------|----------------|--------------|----------------|
|           | AUC (95%CI)  | Youden index  | Sensitivity (%) | Specificity (%) | Threshold value |
| \( \lambda_{Hu} \) | 0.987 (0.965–0.997) | 0.92 | 95.88 | 96.50 | 1.37 |
| NICAP (%) | 0.988 (0.967–0.997) | 0.91 | 96.39 | 94.41 | 6.55 |
| NICPP (%) | 0.686 (0.628–0.741) | 0.27 | 68.04 | 58.74 | 40.15 |
| ICD       | 0.909 (0.868–0.940) | 0.67 | 71.54 | 95.10 | 0.70 |
| AIF       | 0.989 (0.968–0.998) | 0.93 | 96.91 | 95.80 | 0.47 |
|           | 1.000 (0.978–1.000) | 0.98 | 99.48 | 98.25 | 0.85 |
| NICAP (%) | 0.997 (0.973–1.000) | 0.97 | 96.91 | 100.00 | 6.10 |
| NICPP (%) | 0.962 (0.921–0.985) | 0.92 | 99.48 | 92.98 | 16.9 |
| ICD       | 0.717 (0.643–0.784) | 0.44 | 53.85 | 89.74 | 0.40 |
| AIF       | 0.688 (0.612–0.757) | 0.33 | 94.33 | 38.60 | 0.50 |
of metastatic or primary tumors and for the evaluation of the efficacy of tumor treatment. CT perfusion imaging clinical application has not been widely promoted because of the large radiation dose. Mule S, et al. have shown arterial IC to be significantly related to both arterial blood flow and blood volume, confirming the ability of DECT to evaluate both morphological and perfusion changes\(^2\). Sonja Gordic, et al. found strong intra-individual correlations between iodine density and arterial perfusion \((r = 0.75)\)^\(^2\). Our study showed that NICAP and NICPP had high sensitivity and specificity in distinguishing TAA from ANHP. NICAP had high sensitivity and specificity in distinguishing TAA from ANHP, which indicates that NICAP and NICPP could reflect the perfusion information of liver tissue and distinguish TAA from ANHP in the liver.

The current standard for treatment response after TACE is based on morphology, which depends on the experience of the radiologist, DECT parameters could provide quantitative information as a supplement to mRECIST and LI-RADS. Especially for atypical tumors, the quantitative parameters of DECT may help physicians to better judge the effect of treatment and make correct clinical decisions. However quantitative analysis has not been widely promoted, mostly due to the lack of uniformity of equipment and parameters, and some studies are single-center studies, making it difficult to generalize the research results.

The application of DECT in abdominal imaging has been proved to be beneficial, and our research confirms its usefulness compared with conventional CT exam performed at 120 kV, the radiation dose is not increased with DECT and may even be reduced, which benefits from optimization of solutions such as iterative reconstruction technology and the tube current modulation. Thus, the wide application of DECT will not result in an additional radiation dose burden to patients\(^3\).

In our study, lipiodol TACE and DEM-TACE treatments were included. There were no significant differences between the two methods in the parameters of this study. The relevant content was discussed in the supplementary materials.

Our study had some limitations. First, the number of patients was small, and this was a single-center study. If additional data can be obtained, large-scale multicenter studies may more realistically and accurately confirm the results. Second, the pathological results of some patients were not obtained, because patients treated with TACE rarely undergo needle biopsy or surgical resection.

In conclusion, DECT can effectively and quantitatively distinguish different HCC tissues after TACE and may be considered supplementary to LI-RADS v2018 for assessing HCC patients post TACE.

Received: 16 January 2021; Accepted: 10 May 2021
Published online: 27 May 2021

References

1. Liver, E. A. S., Liver, E. A. S. & Canc, E. O. R. T. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma (vol 56, pg 908, 2012). J. Hepatol. 56, 1430–1430 (2012).
2. Park, J. W. et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 35, 2155–2166. https://doi.org/10.1111/liv.12818 (2015).
3. Bruix, J., Reig, M. & Sherman, M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150, 835–853. https://doi.org/10.1053/j.gastro.2015.12.041 (2016).
4. Forner, A., Reig, M. & Bruix, J. Hepatocellular carcinoma. Lancet 391, 1301–1314. https://doi.org/10.1016/S0140-6736(18)30010-2 (2018).
5. Raoul, J. L. et al. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat. Rev. 72, 28–36. https://doi.org/10.1016/j.ctrv.2018.11.002 (2019).
6. Bruix, J., Sala, M. & Llovet, J. M. Chemoembolization for hepatocellular carcinoma. *Gastroenterology* **127**, S179–188. https://doi.org/10.1053/j.gastro.2004.09.032 (2010).
7. Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin. Liver Dis.* **30**, 52–60. https://doi.org/10.1055/s-0030-1247132 (2010).
8. Radiology. A. C. O. CT/MRI LI-RADS v2018. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018 (2018).
9. Krauss, B., Grant, K. L., Schmidt, B. T. & Flohr, T. G. The importance of spectral separation: an assessment of dual-energy spectral separation for quantitative ability and dose efficiency. *Invest. Radiol.* **50**, 114–118. https://doi.org/10.1097/RLI.0000000000001019 (2015).
10. Krauss, B., Grant, K. L., Schmidt, B. T. & Flohr, T. G. The importance of spectral separation an assessment of dual-energy spectral separation for quantitative ability and dose efficiency. *Invest. Radiol.* **50**, 114–118 (2015).
11. Ascenti, G. et al. Distinguishing enhancing from nonenhancing renal masses with dual-source dual-energy CT: iodine quantification versus standard enhancement measurements. *Eur. Radiol.* **23**, 2288–2295. https://doi.org/10.1007/s00330-013-2811-4 (2013).
12. Zhang, P. et al. A novel diagnostic method (spectral computed tomography of sacroiliac joints) for axial spondyloarthritis. *J. Formos. Med. Assoc.* **115**, 658–664. https://doi.org/10.1016/j.jfma.2015.07.003 (2016).
13. Yang, F., Dong, J., Wang, X., Fu, X. & Zhang, T. Non-small cell lung cancer: spectral computed tomography quantitative parameters for preoperative diagnosis of metastatic lymph nodes. *Eur. J. Radiol.* **89**, 129–135. https://doi.org/10.1016/j.ejrad.2017.01.026 (2017).
14. Li, M. et al. Identification of epidermal growth factor receptor mutations in pulmonary adenocarcinoma using dual-energy spectral computed tomography. *Eur. Radiol.* **29**, 2989–2997. https://doi.org/10.1007/s00330-018-5756-9 (2019).
15. NCCN Clinical Practice Guidelines in Oncology Hepatobiliary Cancers, Version 2.2020. https://www.nccn.org/disclosures/guide linepanellisting.aspx (2020).
16. European Association for the Study of the Liver. Electronic address, e. e. e. & European Association for the Study of the, L. EASL clinical practice guidelines: management of hepatocellular carcinoma. *J. Hepatol.* **69**, 182–236. https://doi.org/10.1016/j.jhep.2018.03.019 (2018).
17. Department of Medical Administration, N. H. & Health Commission of the People’s Republic of China. [Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)]. *Zhonghua Gan Zang Bing Za Zhi* **28**(112–128), 2020. https://doi.org/10.3760/cma.j.issn.1007-3418.2020.02.004 (2019).
18. Zhang, X. et al. Axillary sentinel lymph nodes in breast cancer: quantitative evaluation at dual-energy CT. *Radiology* **289**, 337–346. https://doi.org/10.1148/radiol.2018180544 (2018).
19. Liu, X. et al. Papillary thyroid cancer: dual-energy spectral CT quantitative parameters for preoperative diagnosis of metastasis to the cervical lymph nodes. *Radiology* **273**, 167–176. https://doi.org/10.1148/radiol.14140481 (2015).
20. Zhang, X. et al. Gastrointestinal stromal tumor risk classification: spectral CT quantitative parameters. *Abdom. Radiol. (NY)* **44**, 2339–2346. https://doi.org/10.1007/s00261-019-01973-w (2019).
21. Erstad, D. J. & Tanabe, K. K. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. *Ann. Surg. Oncol.* **26**, 1474–1493. https://doi.org/10.1245/s10434-019-07227-9 (2019).
22. Khodarahimi, I. et al. Metal artifact reduction computed tomography of arthroplasty implants: effects of combined modeled iterative reconstruction and dual-energy virtual monoenergetic extrapolation at higher photon energies. *Invest. Radiol.* **53**, 728–735. https://doi.org/10.1097/RLI.0000000000000497 (2018).
23. Dalbeth, N. & Choi, H. K. Dual-energy computed tomography for gout diagnosis and management. *Curr. Rheumatol. Rep.* **15**, 301. https://doi.org/10.1007/s11926-012-0301-3 (2013).
24. Guggenberger, R. et al. Diagnostic performance of dual-energy CT for the detection of traumatic bone marrow lesions in the ankle: comparison with MR imaging. *Radiology* **264**, 164–173. https://doi.org/10.1148/radiol.1211217 (2012).
25. Fletcher, J. G. et al. Observer performance with varying radiation dose and reconstruction methods for detection of hepatic metastases. *Radiology* **289**, 455–464. https://doi.org/10.1148/radiol.2018180125 (2018).
26. Cheng, S. M. et al. Dual energy spectral CT imaging in the assessment of gastric cancer and cell proliferation: a preliminary study. *Sci. Rep.* **8**, 17819. https://doi.org/10.1038/s41598-018-35712-w (2018).
27. Chuang-Bo, Y. et al. Quantitative assessment of the degree of differentiation in colon cancer with dual-energy spectral CT. *Abdom. Radiol. (NY)* **42**, 2591–2596. https://doi.org/10.1007/s00261-017-1176-6 (2017).
28. Mule, S. et al. Can dual-energy CT replace perfusion CT for the functional evaluation of advanced hepatocellular carcinoma?. *Eur Radiol* **28**, 1977–1985. https://doi.org/10.1007/s00330-017-5151-y (2018).
29. Gordic, S. et al. Correlation between dual-energy and perfusion CT in patients with hepatocellular carcinoma. *Radiology* **280**, 78–87. https://doi.org/10.1148/radiol.2015151560 (2016).
30. Thiravit, S., Brunnquell, C., Cai, L. M., Fenlon, M. & Mileto, A. Building a dual-energy CT service line in abdominal radiology. *Eur. Radiol.* https://doi.org/10.1007/s00330-020-07441-0 (2020).

Acknowledgements
We thank the referring technicians for their participation in this study.

Author contributions
P.H., Q.J. and X.Y. designed the research study. Q.J. and X.Y. provided data annotations, performed measurements and composed the manuscript. M.Y. collected the imaging. S.S. and K.Q. collected the clinical data and performed TACE; X.H. and C.C. planned and performed the statistical analysis. Y.L. and Q.L. revised the manuscript and coordinated the study. All authors made substantial contributions to the study. All authors reviewed and approved the manuscript.

Funding
Funding was provided by National Natural Science Foundation of China (Grant No. 81371661).

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-90508-9.

Correspondence and requests for materials should be addressed to P.H.
